ADXN Addex Therapeutics
- 16.1000
- +0.6900+4.48%
- 6.8200
- -9.2800-57.64%
Addex Therapeutics News
Addex Therapeutics' Epilepsy Drug Fails Key Trial
Why Philips Shares Are Trading Higher By 37%; Here Are 20 Stocks Moving Premarket
Shares of Koninklijke Philips N.V. (NYSE:PHG) rose sharply in today's pre-market trading after reporting first-quarter results. The company also resolved the respironics personal injury and medical mo
Addex Therapeutics Announces Lack of Statistical Significance In ADX71149 Phase 2 Epilepsy Study
Addex Therapeutics (NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced
Addex Therapeutics Says Phase 2 Epilepsy Study Did Not Meet Primary Goal
Addex Provides Update on ADX71149 Phase 2 Epilepsy Study
Top Premarket Decliners
Evotec (EVO) shares slumped 32% Wednesday premarket as the company unveiled a "priority reset" of its business following the appointment of a new CEO. Addex Therapeutics (ADXN) fell 13% following a 2.
Addex to Present at the Swiss Biotech Day 2024
Geneva, Switzerland, April 19, 2024 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, announced today that CEO, Tim Dyer, will present at
Addex Therapeutics Full Year 2023 Earnings: Beats Expectations
Earnings Call Summary | Addex Therapeutics(ADXN.US) Q4 2023 Earnings Conference
The following is a summary of the Addex Therapeutics Ltd (ADXN) Q4 2023 Earnings Call Transcript:Financial Performance:Addex secured CHF5 million by spinning out its unpartnered preclinical portfolio
Addex Therapeutics Achieves Stronger Fiscal Position
Addex Therapeutics Logs Decline in FY23 Net Loss; Revenue Rises
Addex Therapeutics (ADXN.SW) said Thursday net loss for full-year 2023 narrowed while revenue increased year over year. Net loss for the 12 months ended Dec. 31, 2023, was 10.6 million francs, compare
Addex Therapeutics GAAP EPS of -CHF 0.14, Revenue of CHF 1.65M
Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
Top-line data from ADX71149 Phase 2 epilepsy study expected by mid-May 2024Launched Neurosterix with Perceptive Advisors, raising USD 63 million in Series A to accelerate development of preclinical portfolio Received CHF
Addex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18, 2024
Geneva, Switzerland, April 11, 2024 – Addex Therapeutics (NASDAQ:ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, today announced that it will issue its Full-Year
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
GainersIN8bio (NASDAQ:INAB) stock increased by 47.7% to $1.61 during Wednesday's pre-market session. The market value of their outstanding shares is at $69.6 million. Jaguar Health (NASDAQ:JAGX) share
Molecular Templates, Acorda Therapeutics, MyMD Pharmaceuticals Among Healthcare Movers
Wall Street Set to Open Slightly Higher as Investors Await Wednesday's Inflation Data
US stocks were set to open slightly higher in Tuesday's trading session as investors looked ahead to March inflation data and the FOMC March meeting minutes slated for release on Wednesday. The Dow Jo
MYMD, MDIA and LIFW Are Among Premarket Gainers
Top Premarket Gainers
Acrivon Therapeutics (ACRV) shares surged 72% in recent premarket activity Tuesday after it said it signed a securities purchase agreement with select current and new accredited investors to issue and
Why Biophytis Shares Are Trading Higher By Around 55%; Here Are 20 Stocks Moving Premarket
Shares of Biophytis S.A. (NASDAQ:BPTS) rose sharply in today's pre-market trading after reporting FY23 results. Biophytis posted a FY23 loss of €0.03 per share, versus a year-ago loss of €0.14 per s
Analysis
Price Target
No Data
